Fully Integrated CDMO Service Provider: From Early-Stage R&D To Commercial Manufacturing

This overview highlights a fully integrated CDMO partner equipped to support programs from early‑stage research through commercial manufacturing. With more than two decades of experience and deep scientific talent spanning small molecules, peptides, oligonucleotides, bioconjugates, ADCs, and emerging modalities, the organization brings scale, technical breadth, and global readiness to complex development pipelines. Extensive R&D infrastructure, commercial‑ready production lines, and flexible technologies — from enzymatic ligation to continuous processing — enable rapid project starts and consistent, high‑quality output.

Dedicated capacity across peptides and oligonucleotides supports the growing demand, while specialized resources, such as fragment banking and advanced monomers, ensure efficient progression from sequence to GMP supply. Access the full asset to learn how these capabilities streamline timelines and de‑risk development.